You are here

Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder

Favorable safety and tolerability, linear pharmacokinetics, and ample CNS exposure of NYX-783 observed in Phase 1
Tuesday, February 19, 2019 - 07:27